冠心方治疗PCI术后气虚痰瘀交阻证临床疗效观察

冠心方治疗PCI术后气虚痰瘀交阻证临床疗效观察【摘要】目的：探讨冠心方在PCI术后气虚痰瘀交阻证患者中的临床疗效。方法：选取PCI术后气虚痰瘀交阻证患者60例，随机分为实验组和对照组各30例。实验组给予冠心方治疗，对照组给予常规西药治疗。比较两组患者的临床症状改善情况、心电图变化、血液流变学指标及生活质量评分。结果：实验组患者在临床症状改善、心电图改善、血液流变学指标改善以及生活质量评分方面均优于对照组（P<0.05）。结论：冠心方对PCI术后气虚痰瘀交阻证患者具有较好的临床疗效，值得进一步推广。【关键词】冠心方；PCI术后；气虚痰瘀交阻证；临床疗效【Abstract】Objective:ToinvestigatetheclinicalefficacyofGuanxinFanginpatientswithpost-PCIcoronaryarterydisease(CAD)complicatedwithQideficiencyandphlegm-stasissyndrome.Methods:Atotalof60patientswithpost-PCICADcomplicatedwithQideficiencyandphlegm-stasissyndromewereselected,randomlydividedintotwogroups:experimentalgroupandcontrolgroupeachcontaining30patients.TheexperimentalgroupwastreatedwithGuanxinFang,whilethecontrolgroupwastreatedwithconventionalWesternmedicine.Theclinicalsymptomsimprovement,electrocardiogramchanges,bloodrheologyindexandqualityoflifescorewerecomparedbetweenthetwogroups.Results:Theexperimentalgrouphadbetterclinicalsymptomsimprovement,electrocardiogramchanges,bloodrheologyindexandqualityoflifescorethanthecontrolgroup(P<0.05).Conclusion:GuanxinFanghasgoodclinicalefficacyinpatientswithpost-PCICADcomplicatedwithQideficiencyandphlegm-stasissyndrome,whichisworthfurtherpromotion.【Keywords】GuanxinFang;Post-PCICAD;Qideficiencyandphlegm-stasissyndrome;Clinicalefficacy銆怉bstract銆慭nObjective:ToinvestigatetheclinicalefficacyofGuanxinFanginpatientswithpost-PCIcoronaryarterydisease(CAD)complicatedwithQideficiencyandphlegm-stasissyndrome.Methods:Atotalof60patientswithpost-PCICADcomplicatedwithQideficiencyandphlegm-stasissyndromewereselected,randomlydividedintotwogroups:experimentalgroupandcontrolgroupeachcontaining30patients.TheexperimentalgroupwastreatedwithGuanxinFang,whilethecontrolgroupwastreatedwithconventionalWesternmedicine.Theclinicalsymptomsimprovement,electrocardiogramchanges,bloodrheologyindexandqualityoflifescorewerecomparedbetweenthetwogroups.Results:Theexperimentalgrouphadbetterclinicalsymptomsimprovement,electrocardiogramchanges,bloodrheologyindexandqualityoflifescorethanthecontrolgroup(P<0.05).Conclusion:GuanxinFanghasgoodclinicalefficacyinpatientswithpost-PCICADcomplicatedwithQideficiencyandphlegm-stasissyndrome,whichis